BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential. On February 24, BridgeBio Pharma ...
BridgeBio announced the FDA approval of Attruby (acoramidis) for the treatment of patients with ATTR-CM. The label looks clean and it includes all the relevant clinical data. Attruby's approval also ...
14d
BridgeBio Pharma CEO Teases Pipeline Launches, Attruby Momentum, and Pfizer Tafamidis Trial Update
CEO Neil Kumar discussed the company’s late-stage pipeline, commercial execution priorities, and the evolving transthyretin amyloid cardiomyopathy (ATTR-CM) market in a conversation with Barclays ...
BridgeBio's lead drug Attruby's approved for ATTR-CM last November has driven a 40% stock increase; however, competition and market dynamics may limit its near-term revenue potential. Despite ...
1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval, indicating strong initial market uptake. Attruby™ is the first and only near-complete ...
- As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete TTR ...
BridgeBio Pharma’s stock jumped more than 6% on Thursday after the drugmaker announced promising sales results for its FDA-approved heart drug as part of its latest quarterly earnings release. The ...
BridgeBio's forward-looking statements in the press release reflect the company's expectations for the commercial success of Attruby, the progression of its clinical trials, and the potential for its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results